Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077604 | 0.85 | ABCC8 (0.44) | ADRA2AADRA2BADRA2C | |
| SCHEMBL7078242 | 0.85 | ADRA2A (0.36) | ADRA2AADRA2BADRA2C | |
| SCHEMBL31379135 | 0.83 | MEN1 (0.34) | MEN1TSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL7563188 | 0.79 | ABCC8 (0.32) | CYP2C19RAB9A | |
| SCHEMBL7079077 | 0.78 | ABCC8 (0.43) | ADRA2AADRA2BADRA2C | |
| SCHEMBL7565551 | 0.78 | MEN1 (0.34) | MEN1TSHRCYP2C19RAB9AKMT2A | |
| SCHEMBL7074970 | 0.76 | ABCC8 (0.41) | MEN1TSHRKMT2A | |
| SCHEMBL7080805 | 0.76 | ABCC8 (0.41) | MEN1TSHRKMT2A | |
| SCHEMBL6802723 | 0.76 | ABCC8 (0.41) | MEN1TSHRKMT2A | |
| SCHEMBL8478611 | 0.74 | ABCC8 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | claimed |
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | ADRA2A 1169/4885ADRA2B 648/4885ADRA2C 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.